Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer

Table 4 Risk factors for biochemical recurrence using the surgical definition and salvage hormonal therapy in patients treated with radical prostatectomy

Variables	Univariate			Multivariate
Variables	HR	95%CI	P	HR	95%CI	P
Risk factors for biochemical recurrence
Age, years	0.967	0.925–1.012	0.163
PSA at diagnosis, ng/mL	1.112	1.049–1.179	< 0.001	1.081	1.015–1.152	0.015
Clinical stage, T2a-c versus 1c	1.791	1.052–3.051	0.032
Gleason grade groups at biopsy	1.528	1.015–2.302	0.042
Positive biopsy core rate, ≥ 34% versus < 34%	1.012	0.550–1.736	0.964
Unfavorable versus favorable	1.808	1.052–3.109	0.032
Surgical margin, positive versus negative	3.191	1.874–5.433	< 0.001	2.169	1.218–3.865	0.009
Pathological T3–4 versus T0–2	2.491	1.470–4.223	0.001	1.847	1.059–3.222	0.030
Pathological Gleason grade groups	1.517	1.200–1.918	0.001	1.240	0.965–1.593	0.092
Risk factors for salvage hormonal therapy
Age, years	0.986	0.924–1.052	0.687
PSA at diagnosis, ng/mL	1.126	1.040–1.220	0.003
Clinical stage, T2a–c versus 1c	3.010	1.339–6.765	0.008
Gleason grade groups at biopsy	3.123	1.661–5.872	< 0.001	2.318	1.199–4.479	0.012
Positive biopsy core rate, ≥ 34% versus < 34%	1.126	0.542–2.340	0.749
Unfavorable versus favorable	3.729	1.523–9.125	0.004
Surgical margin, positive versus negative	2.213	1.080–4.536	0.030	1.610	0.762–3.401	0.211
Pathological T3–4 versus T0–2	4.051	1.165–8.352	< 0.001	2.531	1.185–5.402	0.016
Pathological Gleason grade groups	1.917	1.425–2.579	< 0.001	1.448	1.025–2.045	0.035

ISSN: 1748-717X